Evidence map›Paper›PMID 39456620›Full record

ArticleCancers2024

Enhancing Prostate Cancer Staging: Association of 68Ga-PSMA PET/CT Imaging with Histopathological Grading in Treatment-Naive Patients.

Oleksii Pisotskyi, Piotr Petrasz, Piotr Zorga, Marcin Gałęski, Pawel Szponar, Katarzyna Brzeźniakiewicz-Janus, Tomasz Drewa, Krzysztof Kaczmarek, Michał Cezary Czarnogórski, Jan Adamowicz

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Oleksii PisotskyiDepartment of Urology, Voivodeship Hospital Gorzów Wielkopolski, 66-400 Gorzów Wielkopolski, Poland.
Piotr PetraszDepartment of Urology, Voivodeship Hospital Gorzów Wielkopolski, 66-400 Gorzów Wielkopolski, Poland.
Piotr ZorgaClinical Department of Nuclear Medicine, University of Zielona Góra, 65-002 Zielona Góra, Poland.
Marcin GałęskiDepartment of Urology, Voivodeship Hospital Gorzów Wielkopolski, 66-400 Gorzów Wielkopolski, Poland.
Pawel SzponarDepartment of Urology, Voivodeship Hospital Gorzów Wielkopolski, 66-400 Gorzów Wielkopolski, Poland.
Katarzyna Brzeźniakiewicz-JanusClinic of Hematology, Clinical Oncology, and Radiotherapy with the Chemotherapy Subunit, University of Zielona Góra, 65-002 Zielona Góra, Poland.
Tomasz DrewaChair of Urology and Andrology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-790 Bydgoszcz, Poland.
Krzysztof KaczmarekDepartment of Gynecology and Obstetrics, Voivodeship Hospital Gorzów Wielkopolski, 66-400 Gorzów Wielkopolski, Poland.
Michał Cezary CzarnogórskiLudwik Rydygier Collegium Medicum, Bydgoszcz Nicolaus Copernicus University, 85-790 Bydgoszcz, Poland.
Jan AdamowiczChair of Urology and Andrology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-790 Bydgoszcz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to evaluate the correlation between 68Ga-PSMA uptake in PSMA PET/CT in primary prostate cancer (PC) and its histopathological grading (Gleason score and ISUP grade). Additionally, we compared preoperative biopsy histopathological findings with definitive pathology results in radical prostatectomy (RP) specimens.

methodsWe retrospectively analyzed 86 patients who underwent 68Ga-PSMA PET/CT for primary PC staging, of which 40 patients later underwent radical prostatectomy. PET/CT results, including SUVmax values, were correlated with GS and PSA concentrations. Histopathology reports were analyzed and compared between biopsy and final pathology results following RP.

resultsA significant positive correlation was observed between SUVmax and ISUP grades (Pearson's ρ = 0.34,

conclusion68Ga-PSMA PET/CT demonstrated high sensitivity in detecting high-risk prostate cancer, particularly in patients with GS > 7 or PSA levels ≥ 10 ng/mL. The findings suggest that this imaging modality may be less effective for the staging of patients with lower GS or PSA values, that is, low-risk PCa. Further prospective studies are necessary to validate these results.

Indexed as

68Ga-PSMA PET/CTbiopsy vs. final pathologyhistopathological gradingprostate cancer stagingPSMA expressionSUVmax correlation

Identifiers

PMID39456620
PMCPMC11506593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.